Surprise snub by FDA of AcelRx's Zalviso

The FDA surprised nearly everyone by rejecting AcelRx Pharmaceuticals' new drug application (NDA) for its pre-programmed, non-invasive, handheld system Zalviso, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain.

The FDA surprised nearly everyone by rejecting AcelRx Pharmaceuticals' new drug application (NDA) for its pre-programmed, non-invasive, handheld system Zalviso, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain.

The news of the complete response letter (CRL) came about 10pm EDT on 25 July long-after the US markets had...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category